Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase | Zendy

Millot Frédéric | Zendy; Claviez Alexander | Zendy; Leverger Guy | Zendy; Corbaciglu Selim | Zendy; Groll Andreas H. | Zendy; Suttorp Meinolf | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase

Author(s) -

Millot Frédéric,

Claviez Alexander,

Leverger Guy,

Corbaciglu Selim,

Groll Andreas H.,

Suttorp Meinolf

Publication year - 2014

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.24521

Subject(s) - medicine , imatinib , myeloid leukemia , blood cancer , imatinib mesylate , leukemia , oncology , cancer , pediatrics

Imatinib can be safely discontinued in adults with chronic myeloid leukemia (CML) where there is a prolonged complete molecular response (CMR). No data are available in the pediatric population. Six children with CML discontinued imatinib by themselves. Only three of them were in CMR but for <2 years. A significant increase in transcript level was observed in all six patients after cessation of imatinib and five patients lost the major molecular response (MMR). Four patients regained the MMR within 3 months. Cessation of imatinib in children is not recommended outside a trial, particularly in patients without prolonged CMR. Pediatr Blood Cancer 2014;61:355–357. © 2013 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research